How big is PROCEPT BioRobotics Corp.?

As of Jun 18, PROCEPT BioRobotics Corp. has a market capitalization of 3,265.50 million, with net sales of 249.12 million and a net profit of -90.20 million over the latest four quarters. Shareholder's funds were 402.22 million, and total assets were valued at 534.02 million.

As of Jun 18, PROCEPT BioRobotics Corp. has a market capitalization of 3,265.50 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 249.12 million for the latest four quarters. During the same period, the net profit was recorded at -90.20 million.<BR><BR>As of Dec 24, the reporting period shows that the shareholder's funds amounted to 402.22 million, while total assets were valued at 534.02 million.

What does PROCEPT BioRobotics Corp. do?

PROCEPT BioRobotics Corp. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $69 million and a net loss of $25 million as of March 2025. Key metrics include a market cap of $3.27 billion, a P/E ratio of NA, and a dividend yield of 0%.

Overview: <BR>PROCEPT BioRobotics Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 69 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,265.50 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.68 <BR>Return on Equity: -23.15% <BR>Price to Book: 8.39 <BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold PROCEPT BioRobotics Corp.?

Is PROCEPT BioRobotics Corp. overvalued or undervalued?

As of November 4, 2021, PROCEPT BioRobotics Corp. is considered risky and overvalued, with a Price to Book Value of 8.94 and negative financial metrics, while underperforming the S&P 500 with a year-to-date return of -52.77%.

As of 4 November 2021, the valuation grade for PROCEPT BioRobotics Corp. moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company is currently overvalued, as evidenced by its Price to Book Value of 8.94 and negative metrics such as an EV to EBIT of -33.38 and ROCE of -76.25%. In comparison, peers like iRhythm Technologies, Inc. have a P/E ratio of -111.60, while TransMedics Group, Inc. shows a fair valuation with a P/E of 50.23.<BR><BR>The stock has significantly underperformed against the S&P 500, with a year-to-date return of -52.77% compared to the index's 12.22%. This stark contrast reinforces the notion that PROCEPT BioRobotics Corp. is not only overvalued but also struggling in the current market environment.

Is PROCEPT BioRobotics Corp. technically bullish or bearish?

As of October 31, 2025, PROCEPT BioRobotics Corp. has shifted to a bearish trend with mixed signals across time frames, indicated by bearish daily moving averages and KST, while significantly underperforming the S&P 500 with a year-to-date return of -56.51%.

As of 31 October 2025, the technical trend for PROCEPT BioRobotics Corp. has changed from mildly bearish to bearish. The overall stance is bearish with weak strength indicated by the daily moving averages being bearish and the KST showing bearish signals on both weekly and monthly time frames. The MACD is mildly bullish on the weekly but bearish on the monthly, suggesting mixed signals across different time frames. The RSI is bullish weekly but shows no signal monthly, further contributing to the uncertainty. Additionally, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -56.51% versus the S&P 500's 16.30%.